IXHL (IXHL): a likely value trap?

Avoid — this is a serial-diluting, pre-revenue biotech that just did a 1-for-30 reverse split to avoid delisting; cash won't fund it to profitability.

⚠ TRAP Fundamentals40/100

Down 100% from its all-time high of $1699.20 — now $3.21

Why IXHL dropped

Incannex is a clinical-stage drug developer (no approved products, no revenue) whose stock has collapsed 99.8% from its 2022 peak; the company did a 1-for-30 reverse stock split in February 2026 specifically to regain Nasdaq minimum bid price compliance, and it had previously traded near $0.27, down roughly 81% over the past year pre-split — classic signs of a struggling micro-cap needing constant capital raises.

Fwd P/E -1.9Op margin 0.0%Rev growth —Debt/equity 0.2%Analyst upside 456.3%

How this scored 40/100 ❌ fails 2 hard checks

❌ Fails 2 hard checks — these are pass/fail and override the score entirely.

❌ Makes money not profitable (and no credible path to profit)

❌ Generates cash burns cash (free cash flow $-8M)

✅ Not drowning in debt Debt/equity 0.2% (limit 200%)

✅ Can pay its bills Current ratio 41.6 (needs 1+)

Bar length shows how much each metric is worth — a 10-point metric is twice as wide as a 5-point one. Hover any row for what it means.

Profitability Does it actually make money? 0/25

Operating margin 0.0% 0/9

Net profit margin 0.0% 0/8

Return on equity -117.2% 0/8

Growth Is it getting bigger, or dying? 13/25

Revenue growth unknown 3/9

Earnings growth unknown 2/8

Expected profit change 89.9% 8/8

Value Is it cheap right now? 9/25

Forward P/E -1.9 0/10

PEG ratio unknown 2/8

Analyst target upside 456.3% 7/7

Balance sheet Will it survive? 18/25

Debt / equity 0.2% 10/10

Current ratio 41.6 8/8

Free cash flow $-8M 0/7

🔒 Read the full AI analysis

Create a free account to unlock the bull case and the risks for IXHL — plus today's other picks.

Analysis generated by SmartStonks's AI from public fundamentals and news, first flagged 2026-07-21. Research only — not financial advice.